RxDoctor Payments Data

Ny Tran, NP

Nurse Practitioner · Fairhaven, MANPI 1386246718

Payments from drug & device makers

$2,629in general payments, 2019–2025

Across 69 payments — averaging $38.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$599
  • Johnson & Johnson$384
  • GSK$287
  • Bristol Myers Squibb$227
  • Mirati Therapeutics, Inc.$184
  • E.r. Squibb & Sons, L.L.C.$159
  • plus $788 from 11 others

What the payments were for

  • Food & beverage$2,01176%
  • Education$61824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,629 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$66,120
Medicare patients
506
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate34$73,984
EliquisApixaban42$26,771
XareltoRivaroxaban16$11,786
Tamoxifen Citrate68$2,065
Exemestane16$1,997
Anastrozole75$1,361
Potassium Chloride24$1,129
Oxycodone Hcl81$962
Prochlorperazine Maleate30$660
Letrozole27$650
Dexamethasone51$622
Morphine Sulfate ErMorphine Sulfate14$611
Gabapentin42$596
Acyclovir41$561
Hydroxyurea20$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Scientific Affairs, LLCAbiraterone Acetate$72$73,98434 claims
PfizerEliquis$137$26,77142 claims
Johnson & JohnsonXarelto$384$11,78616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Fairhaven

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →